Loading...
Docoh

Dynavax Technologies (DVAX)

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.

Company profile

DVAX stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

4 Aug 22
12 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
9 Aug 22 Ryan Spencer Common Stock Sell Dispose S No No 16.9157 14,921 252.4K 144,513
9 Aug 22 David F Novack Common Stock Sell Dispose S No No 16.9157 26,250 444.04K 53,213
9 Aug 22 Janssen Robert Common Stock Sell Dispose S No No 16.9157 7,938 134.28K 35,519
8 Aug 22 Cano Francis Common Stock Sell Dispose S No No 17.17 15,000 257.55K 20,834
8 Aug 22 Cano Francis Common Stock Option exercise Acquire M No No 4.97 15,000 74.55K 35,834
8 Aug 22 Cano Francis Stock Option Common Stock Option exercise Dispose M No No 4.97 15,000 74.55K 0
8 Aug 22 Ryan Spencer Common Stock Option exercise Acquire M No No 0 29,663 0 159,434
8 Aug 22 Ryan Spencer RSU Common Stock Option exercise Acquire M No No 0 29,663 0 9,887
8 Aug 22 David F Novack Common Stock Option exercise Acquire M No No 0 26,250 0 79,463
8 Aug 22 David F Novack RSU Common Stock Option exercise Dispose M No No 0 26,250 0 8,750
86.1% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 203 205 -1.0%
Opened positions 22 45 -51.1%
Closed positions 24 30 -20.0%
Increased positions 73 55 +32.7%
Reduced positions 63 60 +5.0%
13F shares Current Prev Q Change
Total value 1.1B 1.36B -19.3%
Total shares 108.87M 104.35M +4.3%
Total puts 1.23M 1.19M +3.2%
Total calls 1.27M 1.3M -2.4%
Total put/call ratio 1.0 0.9 +5.7%
Largest owners Shares Value Change
FHI Federated Hermes 16.54M $179.27M +2.0%
STT State Street 8.5M $92.13M +36.1%
Bain Capital Life Sciences Investors 8.42M $91.22M 0.0%
BLK Blackrock 7.79M $84.49M -0.9%
Bain Capital Life Sciences Fund 7.63M $0 0.0%
Chicago Capital 5.86M $63.48M +2.1%
Vanguard 5.84M $63.34M -1.0%
Partner Fund Management 3.81M $41.25M 0.0%
Fisher Asset Management 3.51M $38.06M -2.6%
Blair William & Co 2.55M $27.66M +13.8%
Largest transactions Shares Bought/sold Change
STT State Street 8.5M +2.25M +36.1%
Edmond De Rothschild Holding 2.45M +1.98M +430.0%
Norges Bank 0 -750K EXIT
D. E. Shaw & Co. 1.4M -679.31K -32.6%
Renaissance Technologies 621.65K +374.1K +151.1%
Two Sigma Investments 1.37M +350.81K +34.5%
GS Goldman Sachs 2.18M +342.36K +18.6%
FHI Federated Hermes 16.54M +330K +2.0%
BAC Bank Of America 643.16K +320.4K +99.3%
Voloridge Investment Management 280.17K -311.99K -52.7%

Financial report summary

?
Competition
PfizerAMGENVBI VaccinesCelgeneIdera PharmaceuticalsRocheNovavaxAgenusNovartisSanofi

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: adware, alleviate, attack, awaiting, belonging, branch, broadly, code, compromise, compromised, conflict, credential, distributor, EC, email, error, extortion, Farma, frequency, hardware, irreparable, Italy, macroeconomic, malware, media, misconduct, Persero, physical, PT, ransomware, ready, Russia, server, software, stuffing, threat, Ukraine, unwilling
Removed: Bavarian, CHMP, commence, HBV, headwind, Inducement, Israel, lifted, likelihood, Nordic, paused, pose, shift, therapy

Patents

Utility
Alkyl Chain Modified Imidazoquinoline TLR7/8 Agonist Compounds and Uses Thereof
3 Feb 22
Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses.
Utility
IMMUNOGENIC COMPOSITION AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
7 Oct 21
The present invention relates to an immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein and adjuvant.
Utility
Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof
21 Sep 21
Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses.
Utility
Combination of a PD-1 Antagonist and CPG-C Type Oligonucleotide for Treating Cancer
1 Jul 21
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (T1119) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
Utility
Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
24 Aug 20
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.